Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25067006 | 0.89 | NLRP3 (0.44) | NLRP3GSRBMP1CA2HSP90AA1 | |
| SCHEMBL20698839 | 0.88 | NLRP3 (0.41) | NLRP3BMP1 | |
| SCHEMBL20698755 | 0.86 | NLRP3 (0.35) | NLRP3GSRSOAT2MYCSOAT1 | |
| SCHEMBL22014583 | 0.86 | NLRP3 (0.42) | NLRP3GSRCA2HSP90AA1CA12 | |
| SCHEMBL22014344 | 0.86 | CA2 (0.35) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL20698687 | 0.86 | NLRP3 (0.42) | NLRP3GSRCA2HSP90AA1CA12 | |
| SCHEMBL20698686 | 0.86 | NLRP3 (0.42) | NLRP3GSRCA2HSP90AA1CA12 | |
| SCHEMBL22014844 | 0.85 | NLRP3 (0.35) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL20698692 | 0.85 | NLRP3 (0.42) | NLRP3GSRCA2HSP90AA1CA12 | |
| SCHEMBL20698694 | 0.85 | NLRP3 (0.50) | NLRP3CA2HSP90AA1CA1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885GSR 2096/4885SOAT2 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.